FDA Approves FoundationOne CDx as Companion Diagnostic for EGFR Therapeutics
Foundation Medicine’s tissue-based test is a genomic profiling test approved as a companion diagnostic for a group of targeted therapies.
Read MorePosted by Andy Lundin | Mar 21, 2022 | Cancer |
Foundation Medicine’s tissue-based test is a genomic profiling test approved as a companion diagnostic for a group of targeted therapies.
Read MorePosted by Andy Lundin | Mar 21, 2022 | Cancer |
Deaths from cancer are expected to increase over the next decade due to screening deficits resulting from COVID-19 pandemic.
Read MorePosted by Andy Lundin | Mar 15, 2022 | Cancer |
There was a 34% drop in cancer diagnosis in Ontario, Canada at the start of the pandemic, followed by a slow and incomplete recovery.
Read MorePosted by Andy Lundin | Mar 11, 2022 | Cancer |
Azra AI is aimed at disrupting manual processes in healthcare to identify positive cancer diagnosis and incidental findings in real time.
Read MorePosted by Andy Lundin | Mar 2, 2022 | Immunoassay Instrumentation, Swabs |
InstaSwab was born out of the COVID-19 pandemic and was found to be up to 20 times more effective in bacterial sample elution.
Read More